Mitochondria have long been suspected to contribute to the biological underpinnings of schizophrenia, a multifactorial disease marked by persistent cognitive, emotional, and behavioral disturbances. However, the precise molecular dysfunctions within mitochondria that drive or exacerbate this condition have remained elusive. Complex I, the first enzyme in the mitochondrial electron transport chain, plays a vital role in ATP production—a process fundamental to cellular energy metabolism. NDUFV2 encodes one of the subunits critical for the assembly and function of this complex. Mutations and expression anomalies in NDUFV2 have been previously linked with psychiatric symptoms, but the regulation of its mRNA and implications for mitochondrial function had not been thoroughly explored until now.

Karry and Ben-Shachar’s research focused on a pseudogene known as NDUFV2P1, which intriguingly shares high sequence similarity with NDUFV2 but is conventionally considered transcriptionally inactive or functionless. Contradicting this traditional dogma, the study revealed that NDUFV2P1 exerts significant functional control by interfering with the mRNA trafficking of its coding counterpart. Through a series of meticulous molecular biology experiments, the study elucidates how NDUFV2P1 binds to the mRNA of NDUFV2, thereby impeding its intracellular transport to mitochondria.

The attenuation of mRNA transport results in an insufficient supply of NDUFV2 subunits at mitochondrial sites, culminating in compromised complex I assembly. This disruption induces a cascade of mitochondrial dysfunctions, including reduced respiratory efficiency and elevated oxidative stress—phenomena frequently observed in postmortem brain analyses of schizophrenia patients. The data shed light on how noncoding genomic elements, previously dismissed as ‘junk DNA,’ may contribute to neuropsychiatric disorders through precise molecular interferences.

The implications of this discovery extend beyond mere molecular pathology. It challenges the mammoth complexity of schizophrenia by linking genetic regulatory processes with fundamental bioenergetic deficits. The researchers employed advanced imaging techniques alongside RNA sequencing to visualize and quantify mRNA distribution patterns within neuronal cells derived from schizophrenia models. These images revealed stark contrasts in mRNA localization between cells expressing normal levels of NDUFV2P1 and those where its expression was experimentally suppressed, thereby reinforcing the causative role of the pseudogene.

Moreover, this research highlights the delicate balance maintained within cellular homeostasis, where pseudogenes may act as molecular sponges or regulators of gene expression rather than redundant genetic fossils. The notion that a pseudogene’s dysregulation can instigate mitochondrial impairment opens a compelling narrative about the hidden layers of genetic regulation involved in psychiatric illnesses. It suggests potential new biomarkers for diagnosis or targets for precision medicine approaches, including RNA-based therapeutics designed to normalize mRNA transport pathways.

Intriguingly, the study also touches upon the broader context of RNA biology within neuropsychiatric conditions, drawing parallels to emerging paradigms where RNA localization and transport are critical to synaptic function and neuronal plasticity. The attenuation of vital mRNA transport challenges previous frameworks that emphasized protein-level defects alone, urging a reevaluation of schizophrenia at the post-transcriptional regulatory level. Such insights could reconceptualize how we approach treatment-resistant symptoms and cognitive decline associated with the disorder.

The mitochondrial dysfunction characterized here aligns with a growing consensus that metabolic abnormalities are not merely ancillary but integral to schizophrenia’s pathology. This work corroborates past mitochondrial DNA studies and functional imaging data, adding molecular specificity to observations of compromised brain energetics. The discovery suggests that targeting mRNA transport mechanisms might restore mitochondrial function, potentially ameliorating neuronal integrity and neurotransmitter balance.

By pinpointing a novel mitochondrial RNA regulatory axis, the researchers provide a molecular foothold to integrate genetics, cell biology, and neural circuit dysfunction in schizophrenia. The careful dissection of NDUFV2P1’s role paves the way for therapeutic strategies that may involve antisense oligonucleotides or small molecule inhibitors aimed at modulating pseudogene interactions. While still in early stages, these mechanistic insights offer hope for more effective interventions that transcend symptom management, moving towards disease modification at a cellular level.

Additionally, the study emphasizes the importance of viewing schizophrenia not solely through the lens of neurotransmitter deficits but as a systemic disorder implicating diverse molecular pathways, including mitochondrial genomics and RNA transport. The authors suggest future research leverage single-cell transcriptomics and live-cell imaging to unravel the temporal dynamics of mRNA trafficking in neural circuits affected by schizophrenia. This could reveal critical windows for intervention during neurodevelopmental stages or disease progression.

Furthermore, the pseudogene’s modulation of mRNA transport may represent a broader principle applicable to other mitochondrial complex subunits and possibly other neurodegenerative or psychiatric diseases. The paradigm introduced here encourages reexamination of pseudogene functions across genomic landscapes, opening novel research territories that merge noncoding RNA biology with mitochondrial physiology. The implications can ripple into studies of aging, neuroinflammation, and metabolic syndromes that share overlapping pathology with schizophrenia.

In conclusion, the identification of NDUFV2P1’s inhibitory effect on NDUFV2 mRNA transport reveals an unexpected molecular pathway contributing to mitochondrial dysfunction in schizophrenia. This insight enriches our understanding of the disease’s etiology, unveiling the intricate interplay between pseudogenes, RNA dynamics, and bioenergetics. As neuroscience seeks to untangle the molecular webs underpinning mental illness, this discovery underscores the transformative potential of integrating genetic, cellular, and systems biology perspectives. Future explorations based on this finding could redefine diagnostic and therapeutic landscapes, offering renewed hope for millions affected by schizophrenia worldwide.

The study by Karry and Ben-Shachar illuminates a new biological frontier, reminding us that even genetic elements once deemed irrelevant can wield profound influence over cellular function and disease. As science continues to delve into these hidden genetic regulators, the promise of unlocking tailored, mechanism-driven treatments becomes ever more attainable, heralding a new era in psychiatric medicine.

Subject of Research: Mitochondrial dysfunction mechanisms in schizophrenia involving mRNA transport regulation by pseudogenes.

Article Title: A new mechanism underlying mitochondrial dysfunction in schizophrenia – attenuated mRNA transport of the complex I subunit NDUFV2 by its pseudogene NDUFV2P1.

Article References:
Karry, R., Ben-Shachar, D. A new mechanism underlying mitochondrial dysfunction in schizophrenia – attenuated mRNA transport of the complex I subunit NDUFV2 by its pseudogene NDUFV2P1. Schizophr (2026). https://doi.org/10.1038/s41537-026-00772-9

Image Credits: AI Generated

Anorexia nervosa has historically been understood as a multifaceted psychiatric illness characterized primarily by restrictive eating behaviors, intense fear of weight gain, and distorted body image. Despite advances in psychological and nutritional treatments, its biological underpinnings remain elusive. The pathway to recovery is often arduous, partly due to a lack of mechanistic clarity about how systemic physiological changes impact brain function and behavior in these patients. The study by Xu, Zhang, Millischer, and colleagues bridges this knowledge gap by probing mitochondrial health in anorexia nervosa patients through the prism of plasma biomarkers.

Mitochondria, often dubbed the “powerhouses of the cell,” are central to energy metabolism, cellular signaling, and apoptosis regulation. Dysfunction in these organelles has been implicated in a variety of neuropsychiatric and metabolic disorders. GDF15 and FGF21, both secreted in response to cellular stress, especially mitochondrial stress, have recently garnered significant attention in translational medicine due to their roles as sensitive indicators of mitochondrial distress and metabolic imbalance. Elevation of these factors in plasma could signal underlying disruptions in mitochondrial homeostasis.

Through meticulous plasma analyses conducted on a cohort of anorexia nervosa patients, the researchers observed a distinct elevation in both GDF15 and FGF21 levels compared to healthy controls. Rather than being uniform across the patient population, these elevated markers delineated a specific subgroup, suggesting heterogeneity in metabolic and mitochondrial function within anorexia patients. This subtype stratification underscores the necessity of personalized approaches in both diagnosis and treatment strategies.

The mechanistic significance of these findings lies in the dual role of GDF15 and FGF21 as molecular beacons of mitochondrial dysfunction and metabolic adaptation. GDF15 is induced under conditions of mitochondrial integrated stress response (ISR) and mediates appetite suppression and energy expenditure adjustments, pathways highly relevant to anorexia nervosa’s pathophysiology. Likewise, FGF21 regulates metabolic homeostasis, including glucose and lipid metabolism, and modulates signaling in peripheral tissues in response to mitochondrial perturbations.

Notably, the interplay between GDF15 and FGF21 implies a coordinated systemic response to chronic metabolic stress, potentially exacerbating anorexia nervosa symptoms, including weight loss and energy scarcity. Elevated GDF15, through central nervous system effects, could contribute to persistent appetite reduction, while increased FGF21 might drive aberrant metabolic adaptations, compounding the catabolic state observed in these patients. Understanding these dynamics offers promising clues into why some anorexia nervosa patients suffer prolonged disease courses.

The study employed state-of-the-art immunoassays and statistical modeling to ensure robust data validation, emphasizing reproducibility and clinical relevance. By leveraging advanced molecular assays sensitive to low-abundance plasma proteins, the investigators were able to delineate subtle yet impactful differences in biomarker expression. Combined with comprehensive clinical phenotyping, the multi-dimensional data approach advances the precision medicine paradigm in psychiatric disorders.

Importantly, the findings challenge the conventional singular focus on psychological factors in anorexia nervosa by highlighting intrinsic biological dysfunctions potentially driving or perpetuating the disorder. Mitochondrial dysfunction may not merely be a downstream consequence of starvation but plays a pivotal role in disease pathophysiology. This paradigm shift encourages future research into mitochondrial-targeted therapies that might ameliorate disease progression or improve recovery rates.

The translational implications of identifying plasma GDF15 and FGF21 as accessible biomarkers are manifold. First, these factors could serve as objective measures to stratify patients for clinical trials, facilitating the development of more effective therapeutic agents tailored to mitochondrial profiles. Second, they could be integrated into routine diagnostics to monitor disease severity and response to treatment, filling a critical gap in clinical practice where subjective assessments dominate.

Furthermore, by shining light on mitochondrial stress responses, the research stimulates questions regarding the origins of mitochondrial impairment in anorexia nervosa. Genetic predispositions, accumulated oxidative damage, inflammatory processes, or environmental factors such as chronic malnutrition might contribute synergistically. Deciphering these causative elements remains a top priority, as interventions aiming to restore mitochondrial function might positively impact synaptic plasticity, neuroendocrine regulation, and ultimately neuropsychiatric stabilization.

The researchers also advocate for longitudinal studies to track fluctuations of GDF15 and FGF21 before, during, and after treatment, which could unravel dynamic changes correlating with clinical outcomes. Such investigations might confirm whether normalization of mitochondrial biomarkers aligns with symptom remission, offering a powerful prognostic tool. These insights could revolutionize how clinicians approach treatment planning and patient monitoring.

In essence, the study reframes anorexia nervosa from a purely psychological disorder to a systemic illness with profound metabolic and mitochondrial components. This holistic perspective invites multidisciplinary collaboration among psychiatrists, molecular biologists, and metabolic specialists to develop integrative care approaches. Targeting cellular energy pathways might represent the next frontier in managing this complex disorder that currently lacks uniformly effective treatments.

Summarily, the elevation of plasma GDF15 and FGF21 heralds a new era of biomarker-driven psychiatry for anorexia nervosa, rooting clinical observations in measurable biological substrates. As the field progresses, the integration of mitochondrial biology into psychiatric research promises to unveil novel mechanisms and therapeutic targets. Patients and caregivers alike may benefit from these scientific advancements by shifting the narrative toward empowering biological understanding and innovative therapies.

The reported findings, published in the journal Translational Psychiatry, thus mark a significant leap forward in psychiatric research. They underscore the necessity of embracing molecular neurobiology alongside traditional psychological frameworks to tackle disorders like anorexia nervosa comprehensively. Future research inspired by this study is poised to transform clinical paradigms and improve patient outcomes worldwide.

With this discovery, the scientific community gains a critical foothold in decoding the intricate metabolic perturbations underlying anorexia nervosa, highlighting mitochondrial dysfunction as a key player. This knowledge deepens our grasp of brain-body interactions in psychiatric illness and underscores the promise of metabolism-centered interventions to effectively combat anorexia nervosa’s debilitating impact.

Subject of Research: Mitochondrial dysfunction indicated by plasma biomarkers in anorexia nervosa patients

Article Title: Elevated plasma GDF15 combined with FGF21 suggests mitochondrial dysfunction in a subgroup of anorexia nervosa patients

Article References:
Xu, J., Zhang, R., Millischer, V. et al. Elevated plasma GDF15 combined with FGF21 suggests mitochondrial dysfunction in a subgroup of anorexia nervosa patients. Transl Psychiatry 15, 215 (2025). https://doi.org/10.1038/s41398-025-03425-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03425-0